5 terminated. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 4 | Terminated 4 |
Follow N-803: new trials by email Literature Review of N-803 trials Research Report on N-803
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy - Advanced Triple Negative Breast Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 3 | 2021-09-08 | 2024-06-12 |
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy Avelumab, N-803, haNK™ - Merkel Cell Carcinoma | Phase 2 | Terminated | ImmunityBio, Inc. | 9 | 2020-02-19 | 2024-08-09 |
| QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Aldoxorubicin HCl, N-803, ETBX-011 - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 9 | 2018-03-19 | 2024-08-09 |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed Aldoxorubicin HCl, ETBX-011, ETBX-021 - Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 4 | 2018-01-09 | 2024-08-05 |
| QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab Rituximab, N-803 - Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Altor BioScience | 43 | 2015-04-17 | 2024-07-03 |
Carcinoma, Merkel Cell (1) · Carcinoma, Squamous Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1)
ImmunityBio, Inc. (4) · Altor BioScience (1)
United States (5)
Bobby Reddy, MD (2)